Which drugs have additional protection certificates in most countries? – DrugPatentWatch
This chart shows the drugs with the most additional protection certificates (SPCs).
SPC is used in the European Union and select others to drive pharmaceutical innovation
compensation for the long time it took to get regulatory approval for the drugs. SPC
enters into force only after the corresponding general patent expires, and usually has a maximum life span of 5 years.
The combined total duration of market exclusivity of general patents and SPCs cannot normally exceed 15 years, but is extended by six months
can be obtained by responding to a request for a pediatric trial.
Pharmaceutical drugs with SPC in most countries are:
- Zejula
- Anoro Ellipta
- biktarvy
- Genvoya
- Harvoni
- Mektovi
- Orkambi
- Stribild
- Technique
- Trelegy Ellipta
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in Which drugs have additional protection certificates in most countries?
